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Organ Transplant Supply and Demand 
Year 
4 
National Organ Transplant Act, 1984 
 Established the Organ Procurement and 
Transplantation Network (OPTN) 
 Network to be operated by private, nonprofit organization under 
federal contract with HHS and HRSA 
 United Network for Organ Sharing (UNOS) operates 
the OPTN  
 Created the current system of organ procurement 
organizations (OPOs) 
 Currently 58 OPOs certified by Centers for Medicare and 
Medicaid Services 
 
HRSA: Health Resources and Services Administration 
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Organ Procurement and Transplantation  
Network Final Rule (42 CFR, Part 121) 
 Structure, membership and oversight function 
Goals and requirements for policy making, 
particularly allocation of organs 
 Waitlist of potential recipients  
 Matches potential recipients with organ donors  
 Donor testing 
 Organ packaging and labeling 
 Data collection and dissemination on pre-transplant 
and post-transplant events  
 Advisory Committee on Organ Transplantation 
 
CFR: Code of Federal Regulations 
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HIV Organ Policy Equity (HOPE) Act  
 HOPE Act signed by US President into law 
November 21, 2013  
 
 Stipulates that the OPTN may develop standards 
for use of organs from HIV–positive donors for 
transplant in individuals who were already 
infected with HIV 
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Required Donor Screening Tests  
for Infectious Pathogens 
Deceased Donors 
 Hepatitis B surface antigen and core antibody 
 Hepatitis C serology, including  
 Hepatitis C nucleic acid amplification testing (NAT) (all donors)* 
 HIV antibody 
 HIV NAT or 4th generation EIA for donors with increased risk* 
 Syphilis 
 Cytomegalovirus serology (CMV) 
 Epstein-Barr virus serology (EBV) 
 Blood culture 
 Urine culture 
 
 
* Pending United Network for Organ Sharing (UNOS) board approval  November 2014 
EIA: Enzyme immunoassays. 
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Typical Questions in Deceased Donor  
Risk Assessment Interview 
 Public Health Service criteria for increased risk for 
incident hepatitis B, hepatitis C, and HIV 
 Sexual exposures, drug use, hemodialysis, inmate of correctional 
facility, or recent sexually transmitted disease 
 Country of origin and previous residence and travel 
 General medical history and medications 
 Recent symptoms, including cough, fever, weight loss or 
headache 
 Human growth hormone exposure for CJD risk 
 Animal exposures  
 Screening for rabies and lymphocytic choriomeningitis virus                 
 
CJD: Creutzfeldt-Jakob Disease  
http://www.publichealthreports.org/issueopen.cfm?articleID=2975 
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Current Waitlist by Organ  
and Age of Candidate 
http://optn.transplant.hrsa.gov/converge/latestData/rptData.asp   
 
41 332 461 
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        Lung                      Heart                    Liver                     Kidney 
    Total Waiting                  Total Waiting                Total Waiting                  Total Waiting  
           1,640                               4,010                            15,687                            101,709 
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Transplants by Organ and  
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       Lung                     Heart                     Liver                      Kidney 
Total Transplants           Total Transplants         Total Transplants          Total Transplants  
           1,923                              2,531                            6,455                              16,896 
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Consequences of the Disparity  
Between Supply and Demand 
http://optn.transplant.hrsa.gov/converge/latestData/rptData.asp 
Wait times vary significantly based on severity of 
illness and other factors 
 
Median national waiting time  
 For kidney – nearly 4 years 
 For liver – nearly 1.5 years 
 
 In 2013 
 6,324 transplant candidates died waiting for an organ     
 4,915 transplant candidates became too sick to transplant 
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Current Screening of Organ Donors for  
Donor-derived Infections 
Daniel Kaul, MD 
Director, Transplant Infectious Disease Services 
University of Michigan  
Chair, Disease Transmission Advisory Committee (DTAC) 
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Donor Screening Tests  
for Selected Situations (not required) 
 Site specific protocols are used 
West Nile virus nucleic acid amplification testing 
 During periods of increased mosquito activity or known outbreaks 
 Trypansoma cruzi (serology) 
 At-risk donors 
 Coccidiomycosis (serology) 
 Southwestern states 
 Strongyloides (serology) 
 Human T-cell lymphotropic virus (HTLV-1) (serology) 
 At-risk donors 
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Recipient Considerations of Accepting Organs 
from Donors with Possible Infection 
 Severity of disease in recipient affects urgency of need  
 Kidney disease rarely requires urgent transplant 
 High score on MELD is an indication for urgent liver transplant 
 
MELD: Model for End Stage Liver Disease 
http://www.unos.org/docs/MELD_PELD.pdf 





















Other Considerations of Accepting Organs 
from Donors with Possible Infection  
 Has the infection been identified, and is effective 
treatment available? 
 Pneumococcal meningitis 
 
 Is the cause of presumed infection unknown?  
 Encephalitis of unknown cause 
 
 Is it a multidrug resistant organism? 
 Toxicity and poor efficacy of available treatment options 
 
What is the extent of the infection? 




An Example of High Risk Donor 
MRSA Endocarditis in Donor 
 Potential donor: male with 
injection drug use 
 MRSA bacteremia 
 Septic emboli to brain 
 Afebrile, on antibiotics for more 
than 48 hours 
 
 Recipient critically ill 
 End stage pulmonary fibrosis  
 Mechanical ventilation in ICU 
 
 Should organs from this 
donor be transplanted? 
 
 
MRSA: Methicillin-resistant Staphylococcus aureus 
ICU: Intensive care unit 
Wendt JM, et al. Am J Transplant, 2014 
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 Both doing well, without infection more than one year 
after transplant 
Outcome of Recipients of  
MRSA Endocarditis Donor 
 Lungs, liver, kidneys, and pancreas transplanted 
    
 Prophylaxis given to  
    all recipients 
     
 Liver and lung recipient  
    with recurrent MRSA 
     
MRSA: Methicillin-resistant Staphylococcus aureus 
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PHS Guideline for Reducing Human Immunodeficiency Virus, Hepatitis B Virus,  
and Hepatitis C Virus Transmission Through Organ Transplantation 
Monitoring Recipients for Post-transplant 
Infection and Donor-derived Disease  
 Post-transplant formal monitoring system limited to  
 Only HIV, HBV, and HCV 
 For other diseases, high index of suspicion needed 
HIV: Human Immunodeficiency virus.                                                                                                    HBV: Hepatitis B virus.   
NAT: Nucleic acid assay testing.                                                                                                            HCV: Hepatitis C virus.  
PHS: Public Health Service.                                                                                                                   Ag/Ab: Antigen and antibody. 
Public Health Reports: July-August 2013 Volume 128 
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Patient Safety Initiatives to Reduce  
Donor-derived Disease 
 Donor centers must report: 
 Relevant new post-transplant findings to all accepting transplant 
centers including cultures, pathology findings, autopsy results 
 Any “new disease or malignancy… that may be transmitted to 
transplant recipients” to the Organ Procurement and Transplant 
Network (OPTN) 
       
 Donor and recipient centers must report:  
 If concern for donor-derived disease arises to the OPTN patient 
safety system including: 
 Infection or disease in both donor and recipient 
 Similar disease in multiple recipients of same donor 
 Other substantive concern for donor origin of disease 
Public Health Reports: July-August 2013 Volume 128 
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 Part of OPTN patient safety program 
 Examine and classify potential donor-derived 
transmission through transplantation of infection    
or malignancy 
 Educate transplant community 
 Help change policy and improve processes 
Membership includes CDC, FDA, transplant centers, 
transplant infectious disease, lab testing, organ 
procurement organizations 
 
Ad Hoc Disease Transmission  
Advisory Committee (DTAC) 









Donors recovered 40,223 31,278 71,501   
  Donors with PDDTE 763   (1.9%) 24   (0.08%) 787     (1.1%) 
  Donors with proven/probable PDDTE 141   (0.4%) 5   (0.02%) 146     (0.2%) 
Total recipient transplants performed 110,402 31,277 141,679 
  Recipients with proven/probable disease 177 (0.16%) 4   (0.01%) 181   (0.13%) 
  Recipient deaths due to  
      proven/probable disease 
39 (0.04%) 1 (0.003%) 40   (0.03%) 
Cumulative Incidence of Disease Transmission: 
PDDTE Reported Through 2013 
Involving Donors Recovered 2008-2012 
33,407 individuals died between 2008-2012 while on the wait list  
PDDTE: Potential donor-disease transmission events 
Disease 
Number of Donor 
Reports 





Virusa 166 48 16 
Bacteriab 118 34   9 
Fungusc   75 31 10 
Mycobacteriad   53 10   3 
Parasitese   35 22   7 
Total Infections 447 145 45 
Infection Reports to the DTAC:  2005-2011 
a  Adenovirus, HBV, HCV, HEV, HIV, HTLV, herpes simplex, influenza, LCMV, Parainfluenza (PIV)-3, Parvovirus B19,  
   rabies, West Nile virus 
b  Acinetobacter, Brucella Enterococcus (including VRE), Ehrlichia spp, E. coli, Gram Positive Bacteria, Klebsiella, 
   Legionella, Listeria, Lyme Disease, Nocardia, Pseudomonas, Rocky Mountain Spotted Fever, Serratia ,  
   S. aureus (MRSA), Streptococcus spp, Syphilis, Veillonella; bacterial meningitis and bacterial emboli 
c  Aspergillus spp, Candida spp, Coccidioides imitis, Cryptococcus neoformans, Histoplasma capsulatum, zygomyces 
d  Tuberculosis, non-TB mycobacteria 
e   Babesia, Balmuthia mandrillaris, Chagas (Trypanosoma cruzi), Naegleria fowleri,miasis, Strongyloides 
DTAC: Disease Transmission Advisory Committee  DDD: Donor-derived disease 
Data includes cases classified as possible, probable or proven from 2005-2007 
as published in AJT, and all reviewed cases from 2008-2011. 
In 2013:  31/284 (11%) cases reviewed by CDC 
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Variability of Reporting Suspected Donor-derived Diseases  






































































Cases reported through 2013. 
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Selected DTAC Patient Safety Projects 
 Demonstrated harm associated with universal HTLV-1/2 
donor testing 
 Formal guidance documents 
 TB risk assessment for living donors 
 Geographic and seasonally limited disease 
 West Nile virus testing 
 Central nervous system infections in deceased donors 
 Ebola virus disease screening for potential donors 
 Translation of public health service guidelines for 
preventing transmission of HIV, HBV, HCV into policy 
 Process to improve communication between organ 
procurement organizations and transplant centers 
 
 
HTLV-1/2: Human T-cell lymphotropic virus, types 1 and 2 
Kaul DR, et al. Am J Transplant 2010. 





Novel Transplant-Associated Infections 
Sherif R. Zaki, MD, PhD 
Chief, Infectious Diseases Pathology Branch 
Division of High-Consequence Pathogens and Pathology 
National Center for Emerging and Zoonotic Infectious Diseases 
Centers for Disease Control and Prevention 
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Unexpected Donor-derived Infections 
Associated with Organ Transplantation 
 
Multiple challenges 
 Unexpected or unrecognized at time of death 
 Not screened for in donor 
 Unknown incidence (presumed low) 
 Associated with significant morbidity and mortality  
 High-profile events 
 
Single donor Multiple recipients 
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NY Times, 2009 (Amoeba ) 
NY Times, 2005 (Rabies) 
NY Times, 2005 (LCMV) 
NY Times, 2002 (WNV) 
Unexpected Donor-derived Infections 
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Novel and Emerging Donor-derived  
Transplant-transmitted Infections, 2002–2014 
West Nile virus   
 6 clusters 
 Lymphocytic choriomeningitis virus 
 5 clusters 
 Rabies  
 2 clusters 
 Balamuthia  
 2 clusters 
Microsporidiosis 
 2 clusters 
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West Nile Virus (WNV) in an Organ Donor and 
Four Transplant Recipients, August 2002 
Organ DONOR 
 Female victim of 




 Patient died 
IHC: Immunohistochemistry 
PCR: Polymerase chain reaction 
Iwamoto M, et al. NEJM 2003. 
One kidney recipient died 
 Thought to have had WNV 
 Seronegative for WNV 
All organ RECIPIENTS  
became febrile 
(2 kidney, liver, heart) 
But IHC and PCR 
showed WNV 
encephalitis 
Blood components from  
63 donors 
 Only one component was 
      WNV IgM positive 
 Only one component  was 
      WNV PCR positive, but  




Viral antigens in red, IHC 
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Single Organ Donor and Four Transplant 
Recipients, 2003 
Organ DONOR 
 Male who died of 
a head trauma 
LCMV: Lymphocytic choriomeningitis virus                                                                                                             Fischer S, et al. NEJM 2006.  
All 4 organ RECEPIENTS 








IHC confirmed LCMV in 
all recipients but lack of 
donor tissue tracing 
back to donor 
.  LCMV culture results 
available after 6 weeks 
Viral antigens in red, IHC 
31 
Second LCMV Cluster in Three Transplant 
Recipients, 2005 
Organ DONOR 
 Woman who died 
of a stroke. 
3 of 4 organ RECIPIENTS  
die 23-26 days  
post-transplant 
1 renal recipient alive 
IHC and PCR 
confirmed LCMV in 







Viral antigens in red, IHC 
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Where Did the Virus Come From? 
 Donor’s daughter had a pet hamster 
that was sick 
 Donor cleaned the cage and where 
the hamster played 
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Amman BR, et al. Emerg Infect Dis 2007.  
Chasing escaped mice  
at Ohio facility 
Viral antigens in red, IHC 
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As a Result, Risk Assessment and  
Screening Questions Improved  
35 
       
 LCMV in a cluster of fatal 
transplant-associated disease 
 3 recipients from single donor 
who died with cerebral 
hemorrhage 
 100 times faster than  
     Sanger sequencing 
 25 million bases in 4 hours 
Viral antigens in red, IHC 
LCMV: Lymphocytic choriomeningitis virus          
Third LCMV Cluster Detected Using  
Advanced Molecular Detection 
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Another Unusual Infection Transmitted from  
Organ Donor to Four Transplant Recipients 
Srinivasan A, et al. NEJM 2005. 
 In 2004, CDC contacted by pathologist in Texas 
 
 Two transplant recipients with unexplained deaths 
  
 Third transplant recipient with altered mental status 
 
 Connection of a common donor among cases was 
determined by families whose loved ones were in the 
intensive care unit 
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“I can’t even swallow my own spit” 
Fallen 3 times  
“Hyperventilating” 
“He is very, very anxious” 
Hospital 
 B 
Agitated, confused, delirious 
Intubated in ER 









Declaration of Death 




Organ donor timeline, April–May 2004 
38 
Organ recipient timeline, April–June 2004 







































































Home X Kidney ICU 
   Liver  Home ICU X 
Home Kidney Mild rejection ICU X 
Background on the Four Recipients  
at Hospital A, Texas 
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Histopathology & IHC, Rabies 
Negri bodies, indicating rabies! 
Viral antigens in red, IHC 
Viral antigens in red, IHC 
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The Persistent Pathologist… 
 
 Recalled 4th death due to encephalitis in organ 
transplant recipient  
 
 Reviewed autopsy 
 Consistent with viral encephalomyelitis due to West Nile virus 
 Received liver transplant 
 Different donor than other cases 
 
 Specimens sent to CDC for further investigation 
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Negri bodies again, indicating rabies! Viral antigens in red, IHC 
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What Was the Source of Infection? 
Was there a link between first three cases  
    and this case? 
 
Was the recipient’s infection unrelated to transplant? 
 
Was the second donor infected? 
 
Was this healthcare-worker transmitted rabies? 
43 




Blood vessel, IHC 
Two Donors for One Transplanted Organ 
 As a result, OPTN changed their 
requirements and instituted better 
tracking of donor organs and tissues 
IHC: Immunohistochemistry 
OPTN: Organ Procurement and Transplantation Network 
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Donor’s serum positive and 
sequence from all three 
recipients was exactly the same 
Rabies variant from  
Mexican Free-Tailed Bat 
Rabies variant from Mexican  
Free-Tailed Bat 
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Raccoon Rabies Virus Variant Transmission 
Through Solid Organ Transplantation, 2013 
IHC: Immunohistochemistry 
PCR: Polymerase chain reaction 
Vora NM, et al. JAMA 2013.  
 Kidney transplant recipient 
died 18 months post-
transplant  
 Donor with a history of 
raccoon exposure died  
with fever, vomiting, 
seizures and dysphagia 
 Rabies positive by 
histopathology and PCR 
 Three other organ 
recipients completed post-
exposure prophylaxis and 
remained asymptomatic 
with serum rabies 
neutralizing antibodies 
Negri bodies Viral antigens in red, IHC 
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Impact from Clusters of Transmitted Rabies  
 From the bat cluster, we learned 
 Rabies could be transmitted through solid organ transplant  
 Tracking the organs and tissues of each donor is critical   
 Instituted better mechanism to track donor and the 
multiple recipients 
 
 From the raccoon cluster, we learned  
 Rabies transmitted from raccoons may have a longer incubation  
 Three recipients were pre-emptively treated  
 Post-exposure prophylaxis was effective in recipients   
who received donor-infected organs, even for rabies  
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An Unusual Infection in an Organ Donor and 
Four Transplant Recipients, 2009 
Organ DONOR 
 4 year-old male  
 Presumed to have died 
from ADEM following 
Influenza A infection 
 Ring-enhancing brain 
lesions 
3 organ RECEPIENTS 
 3 weeks after transplant,  
kidney recipient admitted 
with seizures and altered 
mental status 





From donor autopsy 
tissues, CDC found 
   
 Granulomatous amebic 
encephalitis caused by 
Balamuthia mandrillaris 
 
From further investigation 
   
 Confirmed in both 
kidney recipients  
 One kidney recipient 
died  
 Other three recipients 





Trophozoites Antigen in red, IHC 




Another Balamuthia Infection Transmitted by  
Organ Donor to Four Transplant Recipients, 2010 
 Two of four transplant recipients present  
     with encephalitis 
 Common donor died from presumed stroke 
 
Of the four transplant recipients 
 Liver recipient already died 
 Kidney-pancreas recipient unconscious 






Liver at autopsy 
 Post-transplant day (PTD) 18 
presents with 
 Double vision and difficulty with walking 
 Febrile; loses consciousness 
 Brain biopsy inconclusive 











PCR: Polymerase chain reaction 
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Heart and Other Kidney Recipients 
 Heart and other kidney recipients placed on 
pre-emptive antifungal therapy and survived 
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A  Missed Connection in Donor 





Another Unusual Infection Acquired Through 
Solid Organ Transplantation, 2012 
 37 year-old Mexican woman living in El Paso 
 Died of cerebrovascular accident (CVA) in September 2011 
 
 Left kidney and double lung recipients present with 
fever, tremors, neutropenia and encephalopathy 
 
 Right kidney recipient doing well 
 
 Outside tests show brucella IgM positive serologies 
 
Hocevar S, et al. Ann Intern Med 2014. 
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Left Kidney Recipient  
 Left kidney recipient clinical condition deteriorates, 
necessitating nephrectomy 
 
Micro-abscesses on surface of kidney 
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Microsporidia in Renal Tubules of Donor Left Kidney 
Hematoxylin and eosin             Gram stain                 Immunohistochemistry         Electron micrograph  
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Interstitial nephritis IHC shows Encephalitozoan species 
Biopsy from Right Kidney Recipient  
 All three recipients were infected by same genotype 




Unusual Transplant-associated Infections 
While unusual, they are more common than  
previously suspected 
 Once identified, the next one is easier to recognize 
 Pathology plays a frontline role  
 Recognizing emerging infectious diseases 
 Guiding epidemiologic investigations 
 Donor screening and autopsies are important   
 Donor specimens should be stored  




 Division of High-Consequence Pathogens and Pathology 
 Infectious Diseases Pathology Branch 
 Viral Special Pathogens Branch 
 Poxvirus and Rabies Branch 
 Division of Vector-Borne Diseases 
 Division of Parasitic Diseases 
 Division of Foodborne, Waterborne, and            
Environmental Diseases 
 Division of Healthcare Quality Promotion 
 Office of Blood, Organ, and Other Tissue Safety 
 State Health Departments 




Preventing Unusual  
Transplant-associated Infections 
Sridhar V. Basavaraju, MD 
Medical Officer, Office of Blood, Organ, and Other Tissue Safety 
Division of Healthcare Quality Promotion 
National Center for Emerging and Zoonotic Infectious Diseases 
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Unusual Transplant-transmitted  
Infectious Encephalitis Clusters 








West Nile virus   6 16  4 
LCMV   4 13 10 
Rabies   2   8    5* 
Balamuthia 
mandrillaris 
  2   7     3** 
Total 14 44 22 
* Three recipients received rabies post-exposure prophylaxis and survived.                                         LCMV: Lymphocytic choriomeningitis virus. 
** Four recipients received prophylatic treatment.                                                                                  Basavaraju SV, et al. Emerg Infect Dis 2014. 
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Common Themes in Unusual  
Transplant-transmitted Infection Clusters 
 Donor infection is unrecognized 
 Diseases are rare and infrequently encountered 
 Some donors have no evidence of infectious cause of death 
 Other donors diagnosed with meningoencephalitis of unknown    
cause, but have evidence of infectious etiology including abnormal 
lumbar puncture 
 Disease risk factors are not known (e.g., microsporidia) 
 Donor risks and exposures are not clearly identified 
 Next of kin complete the donor history questionnaire, but they may be  




Common Themes in Unusual  
Transplant-transmitted Infection Clusters 
 Except for West Nile virus, donor screening tests  
are not available  
 
 Difficulty in linking donor and recipient infections 
 Difficult to recognize and diagnose in recipient 
 Geographic distance  
 Timeliness of information 
 
 Lack of active surveillance system  
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Opportunities for Prevention 
Passive versus Active Surveillance 
 Current reporting mechanism is passive  
 Current passive reporting by transplant centers and OPO to 
OPTN/UNOS 
 Only report if concern for donor-derived infection arises 
 
 Establishment of active national surveillance system 
 Routine reporting of total transplants performed 
 Implementation of case definition criteria 




OPO:  Organ procurement organizations 
OPTN: Organ Procurement and Transplantation Network 
UNOS: United Network for Organ Sharing 
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Opportunities for Prevention 
Better Screening of Donors 
 Improve screening of donors 
 Standardized donor history questionnaire across all organ 
procurement organizations 
 
 Balance need to identify donors with an increased 
risk of infectious encephalitis with the need to make 





Improving Recognition of Infectious 
Encephalitis in Donors 
 Identifying donors with increased risk of infectious 
encephalitis through surveillance 
 Recognize signs and symptoms of infectious encephalitis 
 Use all information available (e.g., clinical data and donor history)   
 If increased risk is identified  
 Additional laboratory screening is triggered  
 Follow-up and monitor all recipients 
  
 If infectious encephalitis is identified earlier, 
therapeutic or prophylactic intervention in recipients 
may save lives 
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Risk Stratification Model  
Identifying Donors with Infectious Encephalitis 
1. Clinical tool to identify donors with infectious 
encephalitis 
 Must distinguish infectious from non-infectious encephalitis 
 Use available clinical data including 
 Fever and other symptoms 
 Cerebrospinal fluid analysis 
 Imaging results (e.g., CT, MRI and x-rays)  




Risk Stratification Model 
Optimizing Organ Allocation 
2. Properly allocate organs from donors with   
infectious encephalitis 
 Maximize survival benefit for recipients 
 
3. Re-optimize organ allocation algorithm 
 Reduce the overall “opportunity cost” on the organ match system  
 Ensure the best fit for an organ identified as at increased risk 
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Risk Stratification Model 
Steps to Implementation 
 CDC clinicians and epidemiologists identify clinically 
relevant variables from infectious and non-infectious 
case reports 
 
OPTN/UNOS provides data on patient characteristics 
for those waiting for organs 
 
 Data analyzed by a team in ISyE at Georgia Tech using 
process optimization techniques aimed at solving 
efficiency problems 
OPTN: Organ Procurement and Transplantation Network  
UNOS: United Network for Organ Sharing 
ISyE: Industrial and Systems Engineering Department 
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Improving the Safety of Organ Transplantation 
 Risk for these unusual donor-derived infections is low 
 
 Benefits of organ transplant far outweigh the risks 
 
 Risk assessment should use relevant data to inform 
decision-making 
  
 CDC and organ transplant community continue to  
collaborate to reduce the risk of transplant-transmitted 
infections  
 

